Clinical Report: Prognostic Indicators in Mycosis Fungoides and Sézary Syndrome

Overview

This review synthesizes emerging evidence on prognostic factors in mycosis fungoides (MF) and Sézary syndrome (SS). Key findings include the impact of demographics, clinical stage, and genomic alterations on disease outcomes.

Background

Mycosis fungoides and Sézary syndrome are the most prevalent subtypes of cutaneous T-cell lymphoma, characterized by diverse clinical behaviors and prognoses. Accurate prognostication is crucial for tailoring management strategies.

Data Highlights

No numerical data provided in the source material.

Key Findings

• Traditional TNMB staging remains a key prognostic factor in MF/SS.
• Higher TNMB classification correlates with reduced survival rates.
• Patients with limited skin involvement (T1 classification) exhibit survival rates comparable to control populations.
• Genomic alterations and tumor microenvironment factors are emerging as significant prognostic indicators.
• Integration of traditional and biological prognostic frameworks can enhance treatment strategies.

Clinical Implications

Clinicians should consider both traditional staging and genomic factors when assessing prognosis in patients with MF and SS.

Conclusion

The evolving landscape of prognostic factors in MF and SS highlights the integration of established and novel insights.

Related Resources & Content

1. The ASCO Post, 2019 -- Pembrolizumab for Relapsed or Refractory Mycosis Fungoides and Sézary Syndrome KEY POINTS
2. The ASCO Post, 2018 -- Mogamulizumab-kpkc for Mycosis Fungoides and Sézary Syndrome OF NOTE Monoclonal Antibody for Cutaneous Lymphomas REPORT ADVERSE EVENTS
3. Blood Cancer Journal, 2020 -- Targeted genomic analysis of cutaneous T cell lymphomas identifies a subset with aggressive clinicopathological features
4. Bone Marrow Transplantation, 2020 -- Allogeneic Hematopoietic Stem Cell Transplantation in Advanced Mycosis Fungoides and Sézary Syndrome: Is There a Right Timing for Intervention?
5. Mycosis fungoides and Sézary syndrome: clinical presentation, diagnosis, staging, and therapeutic management - PMC
6. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician’s choice in cutaneous T-cell lymphoma: final data - PMC
7. Genomic profiling of mycosis fungoides identifies patients at high risk of disease progression
8. Mycosis fungoides and Sézary syndrome: clinical presentation, diagnosis, staging, and therapeutic management - PMC
9. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician’s choice in cutaneous T-cell lymphoma: final data - PMC
10. Genomic profiling of mycosis fungoides identifies patients at high risk of disease progression